Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  d'Avila, Joana C ^a,b   Lam, Tina I ^a   Bingham, Deborah ^a   Shi, Jian ^a   Won, Seok J ^a   Kauppinen, Tiina M ^a   Massa, Stephen ^a   Liu, Jialing ^a   Swanson, Raymond A ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Astrocyte; Behavioral; Forelimb; Inflammation; Microglia; Minocycline; Poly(ADP ribose) polymerase; Traumatic brain injury

Indexed keywords

BIOLOGICAL MARKER; CD11B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN NERVE CELL; CELL ACTIVATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME INHIBITION; FORELIMB; GENETIC TRANSCRIPTION; HIPPOCAMPUS; LONG TERM SURVIVAL; MALE; MICROGLIA; NERVE CELL INHIBITION; NONHUMAN; PROTEIN EXPRESSION; RAT; THERAPY DELAY; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN INJURY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; HEMISPHERIC DOMINANCE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOTOR PERFORMANCE; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; BRAIN INJURIES; CELL SURVIVAL; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENCEPHALITIS; FORELIMB; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; MICROGLIA; MOTOR SKILLS; NEURONS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84856989213     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-31     Document Type: Article

References (49)

1. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318. 10.1016/0166-2236(96)10049-7, 8843599.
2. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439. 10.1038/nri2565, 19461673.
3. Loane DJ, Byrnes KR. Role of microglia in neurotrauma. Neurotherapeutics 2010, 7:366-377. 10.1016/j.nurt.2010.07.002, 2948548, 20880501.
4. Yenari MA, Kauppinen TM, Swanson RA. Microglial activation in stroke: therapeutic targets. Neurotherapeutics 2010, 7:378-391. 10.1016/j.nurt.2010.07.005, 20880502.
5. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69. 10.1038/nrn2038, 17180163.
6. Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 2010, 7:494-506. 10.1016/j.nurt.2010.07.003, 2952540, 20880511.
7. Rolls A, Shechter R, Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci 2009, 10:235-241.
8. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol 2006, 18:145-157.
9. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999, 342:249-268. 10.1042/0264-6021:3420249, 1220459, 10455009.
10. Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 2008, 20:294-302. 10.1016/j.ceb.2008.03.006, 2518631, 18450439.
11. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997, 20:252-258. 10.1016/S0166-2236(96)01035-1, 9185306.
12. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 2002, 59:1534-1553. 10.1007/s00018-002-8527-2, 12440774.
13. Kauppinen TM, Swanson RA. Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol 2005, 174:2288-2296.
14. Kauppinen TM, Swanson RA. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 2007, 145:1267-1272. 10.1016/j.neuroscience.2006.09.034, 17084037.
15. Besson VC. Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation. Br J Pharmacol 2009, 157:695-704. 10.1111/j.1476-5381.2009.00229.x, 2721255, 19371326.
16. Besson VC, Zsengeller Z, Plotkine M, Szabo C, Marchand-Verrecchia C. Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat. Brain Res 2005, 1041:149-156. 10.1016/j.brainres.2005.01.096, 15829224.
17. Fink EL, Lai Y, Zhang X, Janesko-Feldman K, Adelson PD, Szabo C, Berger RP, Sarnaik AA, Kochanek PM, Clark RS. Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury. J Cereb Blood Flow Metab 2008, 28:1523-1529. 10.1038/jcbfm.2008.52, 2560585, 18506195.
18. Kauppinen TM, Higashi Y, Suh SW, Escartin C, Nagasawa K, Swanson RA. Zinc triggers microglial activation. J Neurosci 2008, 28:5827-5835. 10.1523/JNEUROSCI.1236-08.2008, 2680357, 18509044.
19. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 2001, 3:1035-1042. 10.1038/ncb1201-1035, 11781564.
20. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 2003, 85:306-317. 10.1046/j.1471-4159.2003.01684.x, 12675907.
21. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006, 103:9685-9690. 10.1073/pnas.0600554103, 1480467, 16769901.
22. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998, 95:15769-15774. 10.1073/pnas.95.26.15769, 28119, 9861045.
23. Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci 2007, 27:3057-3063. 10.1523/JNEUROSCI.4371-06.2007, 17376966.
24. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, Orito K, Egashira N, Iwasaki K, Fujiwara M. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 2008, 39:951-958. 10.1161/STROKEAHA.107.495820, 18258837.
25. Kauppinen TM, Suh SW, Berman AE, Hamby AM, Swanson RA. Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab 2009, 29:820-829. 10.1038/jcbfm.2009.9, 19190653.
26. Hamby AM, Suh SW, Kauppinen TM, Swanson RA. Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion. Stroke 2007, 38:632-636. 10.1161/01.STR.0000250742.61241.79, 17261705.
27. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, Dauerman H, Kumar S, Slomowitz N, Grip L, McCabe CH, Salzman AL. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis 2009, 27:359-364. 10.1007/s11239-008-0230-1, 18535785.
28. Liu J, Solway K, Messing RO, Sharp FR. Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J Neurosci 1998, 18:7768-7778.
29. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990, 10:290-293. 10.1038/jcbfm.1990.47, 1689322.
30. Liu Z, Fan Y, Won SJ, Neumann M, Hu D, Zhou L, Weinstein PR, Liu J. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke 2007, 38:146-152. 10.1161/STROKEAHA.107.492785, 17122429.
31. Allred RP, Adkins DL, Woodlee MT, Husbands LC, Maldonado MA, Kane JR, Schallert T, Jones TA. The vermicelli handling test: a simple quantitative measure of dexterous forepaw function in rats. J Neurosci Methods 2008, 170:229-244. 10.1016/j.jneumeth.2008.01.015, 2394277, 18325597.
32. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol 1994, 4:229-237. 10.1111/j.1750-3639.1994.tb00838.x, 7952264.
33. Pijak MR. Rebound inflammation and the risk of ischemic stroke after discontinuation of aspirin therapy. Arch Neurol 2006, 63:300-301. author reply 301.
34. Shin KH, Nakagawa H, Tsurufuji S. Rebound of vascular permeability response and its inhibition by hydroxyurea in granulomatous inflammation following withdrawal of glucocorticoid therapy. Chem Pharm Bull (Tokyo) 1975, 23:1137-1141.
35. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 2006, 26:1288-1296. 10.1592/phco.26.9.1288, 16945051.
36. Stengel PW, Nickell LE, Wolos JA, Snyder DW. Cessation of dexamethasone exacerbates airway responses to methacholine in asthmatic mice. Eur J Pharmacol 2007, 563:213-215. 10.1016/j.ejphar.2007.02.028, 17374534.
37. Haselkorn ML, Shellington DK, Jackson EK, Vagni VA, Janesko-Feldman K, Dubey RK, Gillespie DG, Cheng D, Bell MJ, Jenkins LW, et al. Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma 2010, 27:901-910. 10.1089/neu.2009.1075, 2943944, 20121416.
38. Chen S, Pickard JD, Harris NG. Time course of cellular pathology after controlled cortical impact injury. Exp Neurol 2003, 182:87-102. 10.1016/S0014-4886(03)00002-5, 12821379.
39. Plesnila N, von Baumgarten L, Retiounskaia M, Engel D, Ardeshiri A, Zimmermann R, Hoffmann F, Landshamer S, Wagner E, Culmsee C. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. Cell Death Differ 2007, 14:1529-1541. 10.1038/sj.cdd.4402159, 17464322.
40. Pullela R, Raber J, Pfankuch T, Ferriero DM, Claus CP, Koh SE, Yamauchi T, Rola R, Fike JR, Noble-Haeusslein LJ. Traumatic injury to the immature brain results in progressive neuronal loss, hyperactivity and delayed cognitive impairments. Dev Neurosci 2006, 28:396-409. 10.1159/000094166, 16943663.
41. Alano CC, Ying W, Swanson RA. Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 2004, 279:18895-18902. 10.1074/jbc.M313329200, 14960594.
42. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010, 30:2967-2978. 10.1523/JNEUROSCI.5552-09.2010, 2864043, 20181594.
43. Koh DW, Dawson TM, Dawson VL. Poly(ADP-ribosyl)ation regulation of life and death in the nervous system. Cell Mol Life Sci 2005, 62:760-768. 10.1007/s00018-004-4508-y, 15868401.
44. LaPlaca MC, Zhang J, Raghupathi R, Li JH, Smith F, Bareyre FM, Snyder SH, Graham DI, McIntosh TK. Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. J Neurotrauma 2001, 18:369-376. 10.1089/089771501750170912, 11336438.
45. Clark RS, Vagni VA, Nathaniel PD, Jenkins LW, Dixon CE, Szabo C. Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J Neurotrauma 2007, 24:1399-1405. 10.1089/neu.2007.0305, 17711401.
46. Satchell MA, Zhang X, Kochanek PM, Dixon CE, Jenkins LW, Melick J, Szabo C, Clark RS. A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma. J Neurochem 2003, 85:697-708. 10.1046/j.1471-4159.2003.01707.x, 12694396.
47. Lescot T, Fulla-Oller L, Palmier B, Po C, Beziaud T, Puybasset L, Plotkine M, Gillet B, Meric P, Marchand-Leroux C. Effect of acute poly(ADP-ribose) polymerase inhibition by 3-AB on blood-brain barrier permeability and edema formation after focal traumatic brain injury in rats. J Neurotrauma 2010, 27:1069-1079. 10.1089/neu.2009.1188, 20380552.
48. Carson MJ, Bilousova TV, Puntambekar SS, Melchior B, Doose JM, Ethell IM. A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease. Neurotherapeutics 2007, 4:571-579. 10.1016/j.nurt.2007.07.002, 2637868, 17920538.
49. Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, Rolls A, Mack M, Pluchino S, Martino G, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009, 6:e1000113. 10.1371/journal.pmed.1000113, 2707628, 19636355.